Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Yuan Fang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2801-2121; OpenAlex author ID A5101650825. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper

Papers 15

  1. DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. Co-author DOI 10.1111/jcmm.16196↗
  2. Paraneoplastic β Cell Dedifferentiation in Nondiabetic Patients with Pancreatic Cancer. Co-author DOI 10.1210/clinem/dgz224↗
  3. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.051↗
  4. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Co-author DOI 10.1038/s41388-019-0701-1↗
  5. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914557116↗
  6. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0965-3↗
  7. IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-3131↗
  8. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  9. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.16732↗
  10. Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance. Last author DOI 10.3892/or.2017.6026↗
  11. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Co-author DOI 10.1097/mpa.0000000000000501↗
  12. mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.7375↗
  13. The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy. First author DOI 10.3109/07357907.2015.1025794↗
  14. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. First author DOI 10.1007/s00441-013-1711-x↗
  15. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-013-0903-z↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiongxiong Lu · 8 shared papers, 2013–2019 · strength 0.44
  2. Chenghong Peng · 8 shared papers, 2013–2019 · strength 0.44
  3. Xiaomei Tang · 5 shared papers, 2016–2019 · strength 0.33
  4. Chenlei Wen · 5 shared papers, 2016–2019 · strength 0.33
  5. Xinjing Wang · 5 shared papers, 2016–2019 · strength 0.32
  6. Baiyong Shen · 6 shared papers, 2013–2018 · strength 0.32
  7. Hao Chen · 6 shared papers, 2013–2018 · strength 0.30
  8. Ping Lu · 3 shared papers, 2018–2019 · strength 0.25
  9. Yongwei Sun · 3 shared papers, 2018–2019 · strength 0.25
  10. Jing Xue · 3 shared papers, 2018–2019 · strength 0.25
  11. Hongzhe Li · 3 shared papers, 2017–2018 · strength 0.20
  12. Zhen Huo · 3 shared papers, 2017–2018 · strength 0.20
  13. Wenhui Lou · 2 shared papers, 2016–2021 · strength 0.18
  14. Xu Han · 2 shared papers, 2016–2021 · strength 0.18
  15. Ningning Niu · 2 shared papers, 2019 · strength 0.18
  16. Qian Zhan · 4 shared papers, 2013–2019 · strength 0.18
  17. Jing Xie · 2 shared papers, 2017–2020 · strength 0.17
  18. Minwei Yang · 2 shared papers, 2018–2019 · strength 0.17
  19. Xiaxing Deng · 3 shared papers, 2013–2018 · strength 0.16
  20. Juanjuan Shi · 2 shared papers, 2018–2019 · strength 0.15
  21. Zhigang Zhang · 2 shared papers, 2018–2019 · strength 0.15
  22. Xiaxing Deng · 3 shared papers, 2013–2017 · strength 0.15
  23. Baiyong Shen · 2 shared papers, 2016–2019 · strength 0.12
  24. Jian-ang Li · 1 shared paper, 2021 · strength 0.12
  25. Yefei Rong · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.